

STATEMENT OF APPROVED BUDGET, UTILIZATION, DISBURSEMENTS AND BALANCES FOR TRUST RECEIPTS
(for Implementing Agency use only)
As of the Quarter Ending June 30, 2021

Department : State Universities and Colleges (SUCs)
Agency : University of the Philippine System
Operating Unit : University of the Philippines, Manila
Organization Code(UACS) :
Fund Cluster : 07 - Trust Receipts
Date Exported : July 12, 2021, 11:15:18 AM

Inter Agency Fund Transfer

Source Agencies and Projects	UACS CODE	Approved Budget			Utilizations					Disbursements					Balances		
		Approved Budgeted Revenue/Receipts	Adjustments (Additions, Reductions, Modifications/ Augmentations)	Adjusted Budget Revenue	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	Unutilized Budget	Unpaid Utilizations (16-19) = (17+18)	
																Due and Demandable	Not Yet Due and Demandable
1	2	3	4	5=(3)+(4)	6	7	8	9	10=(6)+(7)+(8)+(9)	11	12	13	14	15=(11)+(12)+(13)+(14)	16=(5-10)	17	18
CHED		2,000,000.00		2,000,000.00		748,429.59			748,429.59		748,429.59			748,429.59	1,251,570.41		
		2,000,000.00		2,000,000.00		748,429.59			748,429.59		748,429.59			748,429.59	1,251,570.41		
UPM Unfolding the Genomic Diversity and Origin of Multi-Drug Resistant Mycobacterium Tuberculosis in the Philippines (168-6)		2,000,000.00		2,000,000.00		748,429.59			748,429.59		748,429.59			748,429.59	1,251,570.41		
PS		761,416.84		761,416.84		728,904.59			728,904.59		728,904.59			728,904.59	32,512.25		
MOOE		1,238,583.16		1,238,583.16		19,525.00			19,525.00					19,525.00	1,219,058.16		
Dangerous Drugs Board		4,000,000.00		4,000,000.00		180,500.00			180,500.00		180,500.00			180,500.00	3,819,491.20		
		4,000,000.00		4,000,000.00		180,500.00			180,500.00		180,500.00			180,500.00	3,819,491.20		
UPM Development and Validation of a Plastic-Based Microfluidic POCT-Device (E-on) Used to Detect Interactions With Selected New Psychoactive Substances and Pharmaceuticals (184)		4,000,000.00		4,000,000.00		180,500.00			180,500.00		180,500.00			180,500.00	3,819,491.20		
PS		2,852,979.20		2,852,979.20		180,500.00			180,500.00		180,500.00			180,500.00	1,872,478.00		
MOOE		1,787,820.00		1,787,820.00											1,787,820.00		
CO		160,000.00		160,000.00											160,000.00		
UPM AHPD & SRA and Life Insurance, Meals & Accommodation of Healthworkers in Response to COVID-19 Health Emergency (183-28D)		1,421,060.00		1,421,060.00		1,812,469.89			1,812,469.89		1,812,469.89			1,812,469.89	408,590.91		
MOOE		1,421,060.00		1,421,060.00		1,812,469.89			1,812,469.89		1,812,469.89			1,812,469.89	408,590.91		
UPM Development and Implementation of Biosafety and Molecular Biology Training Courses for Lab. Personnel Working in COVID-19 Testing Centers (183-28F)		5,308,819.96		5,308,819.96											5,308,819.96		
PS		4,658,300.00		4,658,300.00											4,658,300.00		
MOOE		534,719.96		534,719.96											534,719.96		
CO		115,000.00		115,000.00											115,000.00		
UPM Development of 5 Clinical Practice Guidelines (183-25)		700,000.00		700,000.00		184,826.67			184,826.67		184,826.67			184,826.67	595,973.33		
MOOE		700,000.00		700,000.00		184,826.67			184,826.67		184,826.67			184,826.67	595,973.33		
UPM Development of Medical Certificate on Cause of Death Instructional Design and Advocacy Initiatives to Philippine Medical Schools Curriculum (183-24A)		5,000,000.00		5,000,000.00		1,876,590.00			1,876,590.00		1,876,590.00			1,876,590.00	3,123,410.00		
PS		320,000.00		320,000.00		320,000.00			320,000.00		320,000.00			320,000.00			
MOOE		4,679,920.00		4,679,920.00		1,556,510.00			1,556,510.00		1,556,510.00			1,556,510.00	3,123,410.00		
DOH		44,825,083.83		44,825,083.83		8,677,609.18			8,677,609.18		8,677,609.18			8,677,609.18	36,147,474.65		
		44,825,083.83		44,825,083.83		8,677,609.18			8,677,609.18		8,677,609.18			8,677,609.18	36,147,474.65		
UPM Effect of Baseline Dengue Serostatus Among Tetravalent Dengue Vaccine CYD-DIV (Dengvaxia) Recipients on Subsequent Virologically Confirmed Dengue in the Philippines (183-21)		8,100,000.00		8,100,000.00		990,339.54			990,339.54		990,339.54			990,339.54	7,109,660.46		
PS		3,564,532.00		3,564,532.00		311,060.35			311,060.35		311,060.35			311,060.35	3,253,471.65		

Source Agencies and Projects	UACS CODE	Approved Budget			Utilizations					Disbursements					Balance		
		Approved Budgeted Revenue/Receipts	Adjustments (Additions, Reductions, Modifications/ Augmentations)	Adjusted Budget Revenue	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	Unutilized Budget	Unpaid Utilizations (16-19) = (17+18)	
																Due and Demandable	Not Yet Due and Demandable
1	2	3	4	5=(3+(-4))	6	7	8	9	10=(6+7+8+9)	11	12	13	14	15=(11+12+13+14)	16=(5-16)	17	18
MOOE		4,535,467.20		4,535,467.20		679,279.19			679,279.19		679,279.19			679,279.19	3,856,188.01		
UPM Evidence Review of Health Technologies (183-27)		200,000.00		200,000.00											200,000.00		
MOOE		200,000.00		200,000.00											200,000.00		
UPM Prevalence of Metabolic and Behavioral Risk Factors Causing Lifestyle-Related Diseases in the National Capital Region (183-23)		1,800,000.00		1,800,000.00		97,141.20			97,141.20		97,141.20			97,141.20	1,702,858.80		
PS		1,005,729.40		1,005,729.40		97,141.20			97,141.20		97,141.20			97,141.20	908,588.20		
MOOE		794,270.60		794,270.60											794,270.60		
UPM Procurement of Supplies, Consumables and other COVID-19 Testing Related Needs in Response to COVID-19 (183-28G)		10,000,000.00		10,000,000.00											10,000,000.00		
MOOE		10,000,000.00		10,000,000.00											10,000,000.00		
UPM Salaries of COVID Laboratory Staff, January to June 2021 (183-28E)		8,658,097.60		8,658,097.60		3,255,405.48			3,255,405.48		3,255,405.48			3,255,405.48	5,402,692.12		
PS		8,658,097.60		8,658,097.60		3,255,405.48			3,255,405.48		3,255,405.48			3,255,405.48	5,402,692.12		
UPM Updating the Philippine Guidelines on Periodic Health Examinations: Phase 1 (183-30)		1,537,906.27		1,537,906.27		987,000.00			987,000.00		987,000.00			987,000.00	550,906.27		
PS		550,906.27		550,906.27											550,906.27		
MOOE		987,000.00		987,000.00		987,000.00			987,000.00		987,000.00			987,000.00			
UPM Updating the Philippine Guidelines on Periodic Health Examinations: Phase 1 (183-30A)		2,100,000.00		2,100,000.00		354,637.20			354,637.20		354,637.20			354,637.20	1,745,362.80		
PS		406,800.00		406,800.00		354,637.20			354,637.20		354,637.20			354,637.20	52,162.80		
MOOE		1,693,200.00		1,693,200.00											1,693,200.00		
UPM Project 2: Developing Immersive Gamification Technology System for Rehabilitation Management of Pediatric Patients with Cerebral Palsy and Mobility Limitations (Phase 1)(187-146)		6,736,770.30		6,736,770.30		869,677.07			869,677.07		869,677.07			869,677.07	5,867,093.23		
PS		3,828,714.00		3,828,714.00		796,922.27			796,922.27		796,922.27			796,922.27	3,031,791.73		
MOOE		1,662,892.30		1,662,892.30		72,754.80			72,754.80		72,754.80			72,754.80	1,596,137.50		
CO		1,245,164.00		1,245,164.00											1,245,164.00		
UPM A Molecular Epidemiologic Analysis of Drug-Resistant Mycobacterium Tuberculosis Isolates Derived from the 3rd Philippine TB Drug Resistance Survey 2018 and Community Based Study (187-150)		3,028,019.00		3,028,019.00		150.00			150.00		150.00			150.00	3,027,869.00		
PS		1,374,384.00		1,374,384.00											1,374,384.00		
MOOE		1,573,635.00		1,573,635.00		150.00			150.00		150.00			150.00	1,573,485.00		
CO		80,000.00		80,000.00											80,000.00		
UPM AB Case Rates Policy: Assessment and Evaluation of Policy Goals (187-153)		894,449.20		894,449.20		150.00			150.00		150.00			150.00	894,299.20		
PS		569,449.20		569,449.20											569,449.20		
MOOE		325,000.00		325,000.00		150.00			150.00		150.00			150.00	324,850.00		
UPM Anti-Coronavirus Therapies to Prevent Progression of COVID-19 (ACT), A RANDOMIZED TRIAL (187-142)		2,979,334.23		2,979,334.23		912,894.63			912,894.63		912,894.63			912,894.63	2,066,439.60		
PS		2,209,964.40		2,209,964.40		784,884.88			784,884.88		784,884.88			784,884.88	1,505,079.60		
MOOE		769,359.83		769,359.83		208,009.83			208,009.83		208,009.83			208,009.83	561,350.00		
UPM Assessment of the Gut Microbiome for COVID-19 Diagnosis and Prognosis (187-131)		4,476,690.00		4,476,690.00		344,050.00			344,050.00		344,050.00			344,050.00	4,132,640.00		
PS		1,230,384.00		1,230,384.00		344,000.00			344,000.00		344,000.00			344,000.00	886,384.00		
MOOE		1,236,306.00		1,236,306.00		50.00			50.00		50.00			50.00	1,236,256.00		
CO		2,010,000.00		2,010,000.00											2,010,000.00		
UPM Association of Abnormal Coagulation Parameters with Adverse Clinical Outcomes among Patients with Moderate to Severe SARS-CoV-2 Infection Admitted in the University of the Philippines - Philippine General Hospital (UP-PGH) 187-147		1,000,000.00		1,000,000.00											1,000,000.00		
PS		368,262.40		368,262.40											368,262.40		

Source Agencies and Projects	UACS CODE	Approved Budget			Utilizations					Disbursements					Balances		
		Approved Budgeted Revenue/Receipts	Adjustments (Additions, Reductions, Modifications/ Augmentations)	Adjusted Budget Revenue	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	Unexpended Budget	Unexpended Utilizations (16-19) = (17+18)	
																Due and Demandable	Not Yet Due and Demandable
1	2	3	4	5=(3+4)	6	7	8	9	10=(6+7+8+9)	11	12	13	14	15=(11+12+13+14)	16=(5-16)	17	18
MOOE		581,737.60		581,737.60											581,737.60		
CO		50,000.00		50,000.00											50,000.00		
UPM Biochemical and Immunologic Characterization and Cross-reactivity Studies of Allergenic Local Pollen Extracts (107-70)		3,789,392.58		3,789,392.58											3,789,392.58		
PS		491,771.20		491,771.20											491,771.20		
MOOE		2,807,621.38		2,807,621.38											2,807,621.38		
CO		490,000.00		490,000.00											490,000.00		
UPM Development of a Cell-Based Immunoassay for Coronavirus Disease 2019 (COVID-19) Serologic Testing (107-140)		4,994,073.84		4,994,073.84		391,452.84			391,452.84		391,452.84			391,452.84	4,602,621.00		
PS		1,182,115.20		1,182,115.20		140,419.20			140,419.20		140,419.20			140,419.20	1,041,696.00		
MOOE		2,414,958.64		2,414,958.64		251,833.64			251,833.64		251,833.64			251,833.64	2,163,125.00		
CO		1,397,000.00		1,397,000.00											1,397,000.00		
UPM Digital Histologic Image Analysis Software for Hirshsprung's Disease (107-95)		644,966.80		644,966.80		644,966.80			644,966.80		644,966.80			644,966.80			
MOOE		644,966.80		644,966.80		644,966.80			644,966.80		644,966.80			644,966.80			
UPM Durability and Extent of Protection for SARS-CoV-2 Antibodies Among Patients with COVID-19 (107-141)		10,799,884.63		10,799,884.63		1,210,944.80			1,210,944.80		1,210,944.80			1,210,944.80	9,588,939.83		
PS		4,151,341.20		4,151,341.20		1,210,794.80			1,210,794.80		1,210,794.80			1,210,794.80	2,948,546.40		
MOOE		6,396,816.45		6,396,816.45		150.00			150.00		150.00			150.00	6,396,666.45		
CO		251,726.98		251,726.98											251,726.98		
UPM Exposure of Reproductive Aged Pregnant and Non-Pregnant Women to Common Environmental Pollutants: Implications to their Reproductive Health, Pregnancy and Fetal Outcomes (107-151)		6,131,845.60		6,131,845.60		75.00			75.00		75.00			75.00	6,131,770.60		
PS		1,564,723.20		1,564,723.20											1,564,723.20		
MOOE		2,417,122.40		2,417,122.40		75.00			75.00		75.00			75.00	2,417,047.40		
CO		2,150,000.00		2,150,000.00											2,150,000.00		
UPM Formulation and Standardization of Precious Hydrochloride - Methylprednisolone Sodium Succinate Powder for Injection (107-156)		4,664,424.20		4,664,424.20											4,664,424.20		
PS		1,237,598.40		1,237,598.40											1,237,598.40		
MOOE		1,191,825.80		1,191,825.80											1,191,825.80		
CO		2,235,000.00		2,235,000.00											2,235,000.00		
UPM Genetics, Immunological and Neurological Long-term Consequences in Prospective COVID-19 Cohort in Thailand, Japan, Philippines, and USA (107-155)		2,919,846.87		2,919,846.87											2,919,846.87		
PS		718,363.20		718,363.20											718,363.20		
MOOE		2,051,482.87		2,051,482.87											2,051,482.87		
CO		150,000.00		150,000.00											150,000.00		
UPM Immune Cell Phenotype Characterization of Moderate to Severe Coronavirus Disease 2019 (COVID-19) Patients at the Philippine General Hospital (107-128A ARCHER program, PCHRD GIA fund)		738,689.88		738,689.88											738,689.88		
PS		717,265.20		717,265.20											717,265.20		
MOOE		21,424.68		21,424.68											21,424.68		
UPM Intra-island Zoonotic Transmission of Schistosomiasis in Leyte, the Philippines (107-137)		1,851,122.02		1,851,122.02	150.00				150.00	150.00				150.00	1,851,972.02		
PS		577,387.20		577,387.20											577,387.20		
MOOE		1,274,734.82		1,274,734.82	150.00				150.00	150.00				150.00	1,274,584.82		
UPM Isolation and Characterization of Antimicrobial-Producing Microorganisms From Mangrove Soils of Alabat Island, Quezon (107-154)		9,861,748.40		9,861,748.40		150.00			150.00		150.00			150.00	9,861,598.40		
PS		1,093,454.40		1,093,454.40											1,093,454.40		

Source Agencies and Projects	UACS CODE	Approved Budget			Utilization					Disbursements					Balance		
		Approved Budgeted Revenue/Receipts	Adjustments (Additions, Reductions, Modifications/ Augmentations)	Adjusted Budget Revenue	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	Unutilized Budget	Unspent Utilization (10-19) = (17+18)	
																Due and Demandable	Not Yet Due and Demandable
1	2	3	4	5=(3+(-4))	6	7	8	9	10=(6+7+8+9)	11	12	13	14	15=(11+12+13+14)	16=(5-10)	17	18
MOOE		3,318,294.00		3,318,294.00		150.00			150.00		150.00			150.00	3,318,144.00		
CO		5,450,000.00		5,450,000.00											5,450,000.00		
DOST		681,172,141.12		681,172,141.12	314,173.48	17,558,218.42			17,872,391.90	314,173.48	17,558,218.42			17,872,391.90	663,299,749.22		
		681,172,141.12		681,172,141.12	314,173.48	17,558,218.42			17,872,391.90	314,173.48	17,558,218.42			17,872,391.90	663,299,749.22		
UPM Operations Research on the Implementation of the Single Joint Ethics Review Process (107-87)		428,387.65		428,387.65		428,387.65			428,387.65		428,387.65			428,387.65			
MOOE		428,387.65		428,387.65		428,387.65			428,387.65		428,387.65			428,387.65			
UPM Perceptions About Ethics of Public Health Interventions During the COVID-19 Outbreak (107-144)		1,361,279.86		1,361,279.86		726,718.40			726,718.40		726,718.40			726,718.40	634,560.46		
PS		851,114.80		851,114.80		681,568.40			681,568.40		681,568.40			681,568.40	169,546.40		
MOOE		510,164.26		510,164.26		45,150.00			45,150.00		45,150.00			45,150.00	465,014.26		
UPM Performance of a Dengue Anti-NS1 Assay for the Determination of Dengue Serostatus Among Children in the Philippines (107-107)		5,000,000.00		5,000,000.00											5,000,000.00		
CO		5,000,000.00		5,000,000.00											5,000,000.00		
UPM Project 1: Biomarkers of Immune Dysfunction in HIV-Associated Metabolic and Neurocognitive Complications (107-138)		52,404,574.00		52,404,574.00	150.00	732,230.00			732,380.00	150.00	732,230.00			732,380.00	51,672,194.00		
PS		3,157,320.00		3,157,320.00		732,230.00			732,230.00		732,230.00			732,230.00	2,425,090.00		
MOOE		1,552,254.00		1,552,254.00	150.00				150.00	150.00				150.00	1,552,104.00		
CO		47,695,000.00		47,695,000.00											47,695,000.00		
UPM Project 1: i-PIX: Design and Fabrication of External Fixator (107-132)		10,242,440.48		10,242,440.48	150.00	214,119.20			214,269.20	150.00	214,119.20			214,269.20	10,028,171.28		
PS		2,257,513.60		2,257,513.60		214,119.20			214,119.20		214,119.20			214,119.20	2,843,394.40		
MOOE		3,494,926.88		3,494,926.88	150.00				150.00	150.00				150.00	3,494,776.88		
CO		4,490,000.00		4,490,000.00											4,490,000.00		
UPM Project 1: Cessation of Tobacco (Rugby) Addiction in Adolescents: Using a Ratios Model to Test Novel Pharmacological and Behavioral Treatments for Overcoming Withdrawal and Craving (107-130)		38,467,882.29		38,467,882.29		764,374.80			764,374.80		764,374.80			764,374.80	37,702,707.49		
PS		2,683,814.40		2,683,814.40		764,224.80			764,224.80		764,224.80			764,224.80	1,919,589.60		
MOOE		16,667,053.49		16,667,053.49		150.00			150.00		150.00			150.00	16,666,903.49		
CO		19,116,214.40		19,116,214.40											19,116,214.40		
UPM Project 1: Developing Immersive Technology System (ImTS) for the Management of Patients with Dementia and Behavioral and Psychological Symptoms (107-145)		7,608,643.05		7,608,643.05		855,188.05			855,188.05		855,188.05			855,188.05	6,753,455.00		
PS		3,938,748.00		3,938,748.00		770,893.00			770,893.00		770,893.00			770,893.00	3,167,855.00		
MOOE		1,590,895.05		1,590,895.05		84,295.05			84,295.05		84,295.05			84,295.05	1,506,600.00		
CO		2,079,000.00		2,079,000.00											2,079,000.00		
UPM Project 1: Next Generation Sequencing-based ex pression profiling of Breast Cancer among Filipinos and Prediction of Response to Neoadjuvant Therapy for Locoregionally-advanced Breast Cancer in Filipinos (107-139)		21,787,750.80		21,787,750.80		53,858.40			53,858.40		53,858.40			53,858.40	21,733,892.40		
PS		2,642,457.60		2,642,457.60		53,858.40			53,858.40		53,858.40			53,858.40	2,588,599.20		
MOOE		17,705,293.20		17,705,293.20		300.00			300.00		300.00			300.00	17,704,993.20		
CO		1,440,000.00		1,440,000.00											1,440,000.00		
UPM Project 2: OR PETALS: Operating Room Programmable Electronically Targeted Active Lighting System (107-133)		10,968,614.32		10,968,614.32	150.00	321,254.80			321,404.80	150.00	321,254.80			321,404.80	10,647,209.52		
PS		2,549,438.40		2,549,438.40		321,254.80			321,254.80		321,254.80			321,254.80	2,228,183.60		
MOOE		3,247,875.92		3,247,875.92	150.00				150.00	150.00				150.00	3,247,725.92		
CO		5,171,300.00		5,171,300.00											5,171,300.00		

Source Agencies and Projects	UACS CODE	Approved Budget			Utilizations					Disbursement					Balances		
		Approved Budgeted Revenue/Receipts	Adjustments (Additions, Reductions, Modifications/ Augmentations)	Adjusted Budget Revenue	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	Unutilized Budget	Unpaid Utilizations (16-17) = (17+18)	
																Due and Demandable	Not Yet Due and Demandable
1	2	3	4	5=(3+4)	6	7	8	9	10=(6+7+8+9)	11	12	13	14	15=(11+12+13+14)	16=(5-10)	17	18
UPM Project 3: Development of a Safe Lactic Acid Bacteria (Lab)-Based Biofunctional Health-Promoting Food as an Adjunct Intervention for the Management of HIV-Associated Metabolic Complications (107-134)		13,237,226.68		13,237,226.68	150.00	603,988.31			604,138.31	150.00	603,988.31			604,138.31	12,633,088.37		
PS		2,306,044.00		2,306,044.00		603,988.31			603,988.31		603,988.31			603,988.31	1,702,056.69		
MOOE		1,576,181.00		1,576,181.00	150.00				150.00	150.00				150.00	1,576,031.00		
CO		9,355,000.00		9,355,000.00											9,355,000.00		
UPM Project 3: i-Blood: A Compact Device for Measuring Intraoperative Blood Loss in Used Surgical Gaze and Laparotomy packs (107-134)		5,317,768.78		5,317,768.78	150.00	173,129.60			173,279.60	150.00	173,129.60			173,279.60	5,144,489.18		
PS		1,971,955.20		1,971,955.20		173,129.60			173,129.60		173,129.60			173,129.60	1,798,825.60		
MOOE		1,697,813.58		1,697,813.58	150.00				150.00	150.00				150.00	1,697,663.58		
CO		1,648,000.00		1,648,000.00											1,648,000.00		
UPM Project 4: Surgical Innovation and Biotechnology Laboratory (SIBOL): Establishment of the University of the Philippines College of Medicine (UPCM) - PGH SIBOL (107-135)		6,056,723.51		6,056,723.51	150.00				150.00	150.00				150.00	6,056,573.51		
PS		2,581,281.60		2,581,281.60											2,581,281.60		
MOOE		3,475,441.91		3,475,441.91	150.00				150.00	150.00				150.00	3,475,291.91		
UPM Risk Factors, Clinical Characteristics and Transmission Of Covid-19 in Non-Pregnant And Pregnant Women in the Philippines: A MULTICENTER STUDY (107-157)		4,998,251.74		4,998,251.74											4,998,251.74		
PS		696,763.20		696,763.20											696,763.20		
MOOE		2,839,888.54		2,839,888.54											2,839,888.54		
CO		1,667,600.00		1,667,600.00											1,667,600.00		
UPM Seroprevalence of Human Adenovirus 5 Neutralizing Antibodies in an Adult Population from Urban Philippines: Implications on Adenoviral Vector-Based SARS-CoV-2 Vaccines (107-143)		4,999,972.81		4,999,972.81		297,114.92			297,114.92		297,114.92			297,114.92	4,702,857.89		
PS		778,857.60		778,857.60		128,419.20			128,419.20		128,419.20			128,419.20	650,438.40		
MOOE		1,945,664.41		1,945,664.41		168,695.72			168,695.72		168,695.72			168,695.72	1,776,968.69		
CO		2,275,450.00		2,275,450.00											2,275,450.00		
UPM SIBOL Fabrication and Characterization of UV and Hydrogen Peroxide Vaporization for Disinfection of N95 Respirators (107-149)		3,359,609.20		3,359,609.20		259,480.73			259,480.73		259,480.73			259,480.73	3,100,128.47		
PS		605,176.00		605,176.00		259,330.73			259,330.73		259,330.73			259,330.73	425,845.27		
MOOE		884,513.20		884,513.20		150.00			150.00		150.00			150.00	884,363.20		
CO		1,790,000.00		1,790,000.00											1,790,000.00		
UPM Solidarity Vaccine Trial in the Philippines: Randomized Trial of Candidate Vaccines of COVID-19 (107-118)		429,322,490.00		429,322,490.00	313,123.48	7,663,711.62			7,976,835.10	313,123.48	7,663,711.62			7,976,835.10	421,345,654.90		
PS		196,316,358.00		196,316,358.00	313,123.48	7,167,431.62			7,480,555.10	313,123.48	7,167,431.62			7,480,555.10	188,835,002.90		
MOOE		216,214,787.00		216,214,787.00		1,280.00			1,280.00		1,280.00			1,280.00	216,213,507.00		
CO		16,791,345.00		16,791,345.00		495,000.00			495,000.00		495,000.00			495,000.00	16,296,345.00		
UPM Support for the 23rd National Institutes of Health Anniversary (107-140)		99,000.00		99,000.00		90,150.00			90,150.00		90,150.00			90,150.00	8,850.00		
MOOE		99,000.00		99,000.00		90,150.00			90,150.00		90,150.00			90,150.00	8,850.00		
National Commission for Culture and the Arts(NCCA)		360,000.00		360,000.00											360,000.00		
		360,000.00		360,000.00											360,000.00		
UPM Establishment of a Pocket Museum and Online Resource on the History of Rizal Hall and other Historical Buildings in the UPM (105)		360,000.00		360,000.00											360,000.00		
PS		252,000.00		252,000.00											252,000.00		
MOOE		108,000.00		108,000.00											108,000.00		
PhilHealth		203,551.56		203,551.56											203,551.56		


Source Agencies and Projects	UACS CODE	Approved Budget			Utilizations					Disbursements					Balances		
		Approved Budgeted Revenue/Receipts	Adjustments (Additions, Reductions, Modifications/ Augmentations)	Adjusted Budget Revenue	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	1st Quarter Ending March 31	2nd Quarter Ending June 30	3rd Quarter Ending Sept. 30	4th Quarter Ending Dec. 31	Total	Unutilized Budget	Unpaid Utilizations (16-19) = (17+18)	
																Due and Demandable	Not Yet Due and Demandable
1	2	3	4	5=(3)+(4)	6	7	8	9	10=(6)+(7)+(8)+(9)	11	12	13	14	15=(11)+(12)+(13)+(14)	16=(5-10)	17	18
		283,551.56		283,551.56											283,551.56		
UPM Validating the Performance of the National Health Insurance Program (153C)		283,551.56		283,551.56											283,551.56		
MOOE		283,551.56		283,551.56											283,551.56		
PITAHIC		399,823.98		399,823.98		137,375.78			137,375.78		137,375.78			137,375.78	262,448.28		
		399,823.98		399,823.98		137,375.78			137,375.78		137,375.78			137,375.78	262,448.28		
UPM Formulation and in vivo Evaluation Studies of Syrup and Tablet Containing Alternanthera versicolor and Phyllanthus niruri aqueous Crude Extracts for Anemia and Thrombocytopenia (Phase I) 165-16		399,823.98		399,823.98		137,375.78			137,375.78		137,375.78			137,375.78	262,448.28		
PS		267,804.00		267,804.00		38,278.40			38,278.40		38,278.40			38,278.40	236,725.60		
MOOE		132,819.98		132,819.98		187,897.36			187,897.36		187,897.36			187,897.36	25,722.68		
GRAND TOTAL		732,968,608.49		732,968,608.49	314,173.48	27,362,141.69			27,616,315.17	314,173.48	27,362,141.69			27,616,315.17	705,344,285.32		
PS		267,223,866.51		267,223,866.51	313,123.48	28,345,185.95			28,658,389.43	313,123.48	28,345,185.95			28,658,389.43	246,565,557.88		
MOOE		331,633,933.60		331,633,933.60	1,950.00	6,461,955.74			6,463,885.74	1,850.00	6,461,955.74			6,463,885.74	325,178,927.86		
CO		134,182,808.38		134,182,808.38		495,800.98			495,800.98		495,800.98			495,800.98	133,687,007.38		

Certified Correct:


LOVELLE C. SAGUID
Chief Budget Officer


Date:

Certified Correct:


ERWIN A. DANDO, CPA
Chief Accountant


Date:

Recommended By:


MICHAEL L. TELLE, MD, MHPed
Vice Chancellor for Planning and Development

Date:

Approved By:


CARMENCITA D. PADILLA, MD, MAHPS
Chancellor

Date: